Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry

ConjunctivitisFlammer SyndromeMacular DiseasesRetinal DiseasesCataracts

12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry

Acta Ophthalmol

Niedzwiecki M, Hunt A, Nguyen V, Mehta H, Creuzot-Garcher C, Gabrielle PH, Guillemin M, Fraser-Bell S, Arnold J, McAllister IL, Gillies M, Barthelmes D

doi: 10.1111/aos.15014

Macular Diseases

Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry

Ophthalmology.

Bhandari S, Nguyen V, Arnold J, Young S, Banerjee G, Gillies M, Barthelmes D

doi: 10.1016/j.ophtha.2019.10.006.

Macular DiseasesRetinal Diseases

A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept

Acta Ophthalmol.

Spooner K Hong T, Bahrami B, Chang A

doi: 10.1111/aos.13802.

Macular Diseases

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Clin Exp Ophthalmol.

Spooner K, Fraser-Bell S, Hong T, Chang A

doi: 10.1111/ceo.13636.

Macular DiseasesRetinal Diseases

Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial

Ophthalmol Retina.

Vader MJC, Schauwvlieghe AME, Verbraak FD, Dijkman G, Hooymans JMM, Los LI, Zwinderman AH, Peto T, Hoyng CB, van Leeuwen R, Vingerling JR, de Jong-Hesse Y, van Lith-Verhoeven JJC, Dijkgraaf MGW, Schlingemann RO, Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) Study Group.

doi: 10.1016/j.oret.2019.12.019.

Macular DiseasesRetinal Diseases

Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection

Br J Ophthalmol.

Yoo JH, Ahn J, Oh J, Cha J, Kim SW

doi: 10.1136/

Macular Diseases

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study

JAMA Ophthalmol.

Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group

doi: 10.1001/jamaophthalmol.

COMMENTED

Macular Diseases

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial

JAMA Ophthalmol.

Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S, LEAVO Study Group.

doi: 10.1001/

Macular Diseases

Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion

Ophthalmol Retina.

Yiu G, Welch RJ, Wang Y, Wang Z, Wang PW, Haskova Z

doi: 10.1016/j.oret.2019.08.009.

Related content

12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry

Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry

A meta-analysis of patients with treatment-resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept

Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab

Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Retinal Vein Occlusion: The Bevacizumab to Ranibizumab in Retinal Vein Occlusions (BRVO) study, a Randomized Trial

Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial

Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion